Editor’s note: This article and headline was corrected to read iloprost, not albuterol.
A single dose of the drug iloprost (also known as Ventavis) had clinical benefits for COPD patients with pulmonary hypertension, with the greatest benefit for severe COPD-PH patients.
More than half of COPD patients are known to develop PH (COPD-PH). To date, the only treatment shown to slow or reverse disease progression is long-term oxygen therapy.
Results showed that a single dose of inhaled Ventavis led to a substantial improvement in hemodynamic parameters (mean pulmonary artery pressure, pulmonary vascular resistance or PVR, and volume of blood being pumped by the heart), without compromising hypoxic vasoconstriction and gas exchange.
The title is incorrect. The article is about iloprost (Ventavis), not Albuterol. 🙂
The title is incorrect. The article is about iloprost (Ventavis), not albuterol.
Albuterol??? I think there is a info mix up in this article… do you mean Iloprost?
Albuterol is not the drug in the paper. It is iloprost, a known inhaled prostacyclin.